Israel’s BioSight has announced positive results of the Phase 1/2 study of its lead product BST-236, a novel cytarabine pro-drug, as a single agent for induction therapy in acute leukemia patients. It was effective on many patients who had failed … Continue reading →

Israel’s BioSight has reported that in treating patients with its Astarabine leukemia treatment, three patients with late-stage leukemia achieved full remission to date. Good results were also reported for older patients over 80. http://www.globes.co.il/en/article-biosight-completes-successful-cancer-drug-trial-1001165482

Israel’s BioSight is pleased with its Phase I/IIa study to evaluate the safety and efficacy of its Astarabine treatment for Acute Myeloid Leukemia (AML) and relapsed/refractory Acute Lymphoblastic Leukemia (ALL).  Full results later this year.  (See also 1st Nov newsletter). … Continue reading →

Israel’s BioSight has developed the amino acid astrabine which acts as a “Trojan Horse” chemotherapy treatment that kills leukemia cells without harming healthy tissue. Astrabine closely resembles a protein called aspargine that leukemia cells depend on and the cancer cells … Continue reading →